MusthInsider

Latest On Bellicum Pharmaceuticals, Inc (BLCM):

Updated on: March 18, 2021

Date/Time	Type	Description	Signal
2023-03-16 00:10 EST	News	Bellicum plunges 49% after ending trials for CAR-T candidates	N/A
2022-11-11 07:00 EST	News	Bellicum Pharmaceuticals GAAP EPS of -$0.23, revenue of $1M	N/A
2022-08-11 23:46 EST	News	Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56	N/A
2022-05-13 08:00 EST	News	Bellicum Pharmaceuticals GAAP EPS of -$0.25 beats by $0.42	N/A
2021-12-14 11:00 EST	News	Bellicum regains Nasdaq continued listing requirements compliance	N/A
2021-12-06 12:13 EST	News	Bellicum Pharma reports positive BPX-601 data in prostate cancer; secures $35M capital	N/A
2021-09-19 04:23 EST	News	Bellicum Pharmaceuticals (BLCM ) Investor Presentation - Slideshow	N/A
2021-09-01 20:02 EST	News	Bellicum soars 12% amid license deal with Texas MD Anderson Cancer Center	N/A
2021-08-13 09:53 EST	News	Bellicum Pharmaceuticals EPS beats by $0.63	N/A
2021-07-20 21:38 EST	News	Bellicum inks license agreement with UNC Lineberger and Mass General	N/A
2021-03-31 17:42 EST	News	Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2020 Results - Earnings Call Transcript	N/A
2021-03-30 22:02 EST	News	Bellicum Pharmaceuticals EPS beats by $2.04	N/A
2021-01-28 21:07 EST	News	FDA lifts clinical hold on Bellicum's BPX-601 cancer trial	N/A
2021-01-13 11:14 EST	Analyst Rating	The Analyst Target Price has decreased from $4.75 to $4.5.	Neutral
2021-01-02 15:16 EST	Financials	Company financials have been released.	Neutral
2020-12-13 03:21 EST	Financials	Company financials have been released.	Neutral
2020-12-10 08:48 EST	News	Enrollment underway for Bellicum's BPX-603 in early-stage solid tumor study	N/A
2020-12-07 23:18 EST	News	FDA puts clinical hold on Bellicum's cancer therapy	N/A
2020-11-15 11:27 EST	Financials	Company financials have been released.	Neutral
2020-11-10 03:17 EST	Financials	Company financials have been released.	Neutral
2020-11-09 03:23 EST	Financials	Company financials have been released.	Neutral
2020-11-09 03:23 EST	Analyst Rating	The Analyst Target Price has decreased from $6.75 to $4.75.	Neutral
2020-11-06 11:16 EST	Earnings Estimate	An EPS average of -$1.52 is estimated for the quarter ending on March 31, 2021.	Sell
2020-11-06 03:36 EST	News	Bellicum Pharmaceuticals reports Q3 results	N/A
2020-11-03 15:17 EST	Analyst Rating	The Analyst Target Price has decreased from $12.83 to $6.75.	Neutral
2020-11-02 16:43 EST	Analyst Rating	The Analyst Target Price has decreased from $17.33 to $12.83.	Neutral
2020-11-01 17:19 EST	Financials	Company financials have been released.	Neutral
2020-10-30 12:05 EST	News	Bellicum launches $25M underwritten offering	N/A
2020-10-30 12:05 EST	News	Bellicum Pharma slashes headcount by 79%	N/A
2020-09-24 00:16 EST	Financials	Company financials have been released.	Neutral
2020-09-16 14:07 EST	News	Bellicum Pharmaceuticals: Accumulating At This Valuation	N/A
2020-09-12 00:16 EST	News	Bellicum Pharmaceuticals (BLCM) Investor Presentation - Slideshow	N/A
2020-08-09 00:16 EST	Financials	Company financials have been released.	Neutral
2020-08-07 13:41 EST	News	Bellicum Pharmaceuticals EPS misses by $5.68	N/A
2020-08-07 13:39 EST	News	Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q2 2020 Results - Earnings Call Transcript	N/A
2020-07-31 00:21 EST	Financials	Company financials have been released.	Neutral
2020-07-28 12:18 EST	Financials	Company financials have been released.	Neutral
2020-07-23 16:26 EST	Financials	Company financials have been released.	Neutral
2020-07-10 08:15 EST	Financials	Company financials have been released.	Neutral
2020-06-15 20:13 EST	News	Bellicum Pharma on go with mid-stage study of BPX-603 for HER2+ solid tumors	N/A
2020-06-02 08:15 EST	Earnings Estimate	An EPS average of -$3.80 is estimated for the quarter ending on September 30, 2020.	Sell
2020-05-31 16:43 EST	Financials	Company financials have been released.	Neutral
2020-05-15 20:12 EST	Financials	Company financials have been released.	Neutral
2020-05-10 16:37 EST	Financials	Company financials have been released.	Neutral
2020-05-10 03:48 EST	News	Bellicum Pharmaceuticals EPS of $1.09	N/A
2020-05-03 08:18 EST	Financials	Company financials have been released.	Neutral
2020-04-11 04:27 EST	News	Bellicum Pharmaceuticals EPS misses by $1.49	N/A
2020-04-07 08:14 EST	Analyst Rating	The Analyst Target Price has increased from $17.25 to $17.33.	Buy
2020-04-07 00:20 EST	Financials	Company financials have been released.	Neutral
2020-03-19 13:02 EST	Insider Trade	Richard A. Fair has acquired 5,000 shares indirectly via Trust.	Buy

About Bellicum Pharmaceuticals, Inc (BLCM):

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. It has collaboration and license agreements with Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

See Advanced Chart

General

Name Bellicum Pharmaceuticals, Inc
Symbol BLCM
Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
SectorHealthcare
IndustryBiotechnology
Full Time Employees 107
Last Split Factor1:10
Last Split Date2020-02-06
Fiscal Year EndDecember
IPO Date2014-12-18
Gic SectorHealth Care
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic SubIndustryBiotechnology
Web URLhttp://www.bellicum.com

Valuation

Price/Sales (Trailing 12 Mt.) 4.27
Price/Book (Most Recent Quarter) 40.34
Enterprise Value Revenue 0.48
Enterprise Value EBITDA 0.05

Financials

Most Recent Quarter 2020-09-30
Next Quarter EPS Estimate -$2.40
Operating Margin -1057%
Return on Assets -35%
Revenue 5.13 million
Earnings Per Share -$2.31
Revenue Per Share $1.02
Gross Profit -55328000
Quarterly Earnings Growth -64.7%

Highlights

Market Capitalization 25.07 million
EBITDA -92547000
Analyst Target Price $4.5
Book Value Per Share $0.25

Share Statistics

Shares Outstanding 6.1 million
Shares Float 4.1 million
% Held by Insiders 32%
% Held by Institutions 23.9%
Shares Short 689053
Shares Short Prior Month 603899
Short Ratio 0.49
Short % of Float 11%
Short % of Shares Outstanding 11%

Technicals

Beta 1.78
52 Week High $9.56
52 Week Low $2.62
50 Day Moving Average 4.7
200 Day Moving Average 4.62

Dividends

Dividend Date 2020-02-06
ExDividend Date N/A
Dividend Yield 0%

Bellicum Pharmaceuticals, Inc (BLCM) Dividend Calendar:

BLCM's last dividend payment was made to shareholders on February 6, 2020.

Ex-Dividend Date	Payment Date	Record Date	Declared Date	Amount

Bellicum Pharmaceuticals, Inc (BLCM) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

Quarter Date	Report Date	Actual Revenue	Reported EPS	EPS Estimate	Deviation from Estimate
2020-09-30	2020-11-05	$N/A	-$0.18	-$3.15	94.28%
2020-06-30	2020-08-06	$N/A	-$8.55	-$2.87	-197.91%
2020-03-31	2020-05-07	$N/A	$1.09	-$2.73	139.93%
2019-12-31	2020-03-12	$5.13 million	-$5.82	-$4.34	-34.26%
2019-09-30	2019-11-06	$N/A	-$6.80	-$5.30	-28.3%
2019-06-30	2019-08-05	$1.39 million	-$5.80	-$5.40	-7.41%
2019-03-31	2019-05-07	$516000	-$5.50	-$5.82	5.5%
2018-12-31	2019-03-12	$312000	-$6.30	-$6.46	2.48%
2018-09-30	2018-11-06	$292000	-$5.50	-$5.68	3.08%
2018-06-30	2018-08-07	$362000	-$6.00	-$5.63	-6.67%
2018-03-31	2018-05-08	$154000	-$6.80	-$7.04	3.45%
2017-12-31	2018-03-13	$-69000	-$6.60	-$6.97	5.33%
2017-09-30	2017-11-07	$126000	-$7.10	-$7.40	4.05%
2017-06-30	2017-08-08	$-128000	-$7.40	-$6.63	-11.64%
2017-03-31	2017-05-08	$128000	-$8.00	-$7.04	-13.68%
2016-12-31	2017-03-13	$81000	-$7.40	-$7.33	-0.97%
2016-09-30	2016-11-09	$114000	-$6.60	-$6.34	-4.1%
2016-06-30	2016-08-08	$101000	-$6.10	-$5.80	-5.17%
2016-03-31	2016-05-09	$92000	-$5.60	-$5.10	-9.8%
2015-12-31	2016-03-14	$34000	-$6.30	-$4.20	-50%
2015-09-30	2015-11-09	$57000	-$0.51	-$0.38	-34.21%
2015-06-30	2015-08-13	$84000	-$0.40	-$0.49	18.37%
2015-03-31	2015-05-11	$107000	-$0.30	-$0.30	0%
2014-12-31	2015-03-11	$15000	-$2.02	-$0.37	-445.95%

Bellicum Pharmaceuticals, Inc (BLCM) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:

Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares

Cash Flow:

Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures

Balance Sheet:

Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Bellicum Pharmaceuticals, Inc (BLCM) Chart:

Bellicum Pharmaceuticals, Inc (BLCM) News:

Below you will find a list of latest news for Bellicum Pharmaceuticals, Inc (BLCM) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Bellicum Pharmaceuticals, Inc (BLCM) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date	Strike	Last Price	Type	Volume	Open Interest	Implied Volatility	In The Money	Change	Change Percent

Latest BLCM Trades:

Date	Shares	Price
Jun 13, 2022 6:12 PM EST	23	$1.15
Jun 13, 2022 7:33 PM EST	55	$1.21
Jun 13, 2022 7:43 PM EST	100	$1.12
Jun 13, 2022 7:55 PM EST	100	$1.1
Jun 13, 2022 7:56 PM EST	100	$1.08

Bellicum Pharmaceuticals, Inc (BLCM) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date	Form Type	Form Name	Link
2020-06-24	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000019/0001358403-20-000019-index.htm
2019-07-29	UPLOAD	SEC-generated letter	https://www.sec.gov/Archives/edgar/data/1358403/000000000019011666/0000000000-19-011666-index.htm
2019-09-06	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1358403/000001961719000171/0000019617-19-000171-index.htm
2019-02-04	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1358403/000021545719003311/0000215457-19-003311-index.htm
2019-07-10	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1358403/000021545719008301/0000215457-19-008301-index.htm
2019-08-26	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1358403/000091957419005539/0000919574-19-005539-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1358403/000091957420001657/0000919574-20-001657-index.htm
2020-02-12	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1358403/000103738920000087/0001037389-20-000087-index.htm
2020-01-24	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1358403/000110465920006801/0001104659-20-006801-index.htm
2019-02-13	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1358403/000114420419007218/0001144204-19-007218-index.htm
2019-08-22	SC 13D	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1358403/000114420419041148/0001144204-19-041148-index.htm
2018-12-19	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000119312518353239/0001193125-18-353239-index.htm
2019-05-08	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1358403/000119312519139904/0001193125-19-139904-index.htm
2019-06-06	DEFR14A	Revised definitive proxy soliciting materials	https://www.sec.gov/Archives/edgar/data/1358403/000119312519166345/0001193125-19-166345-index.htm
2019-06-19	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000119312519176497/0001193125-19-176497-index.htm
2019-06-24	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1358403/000119312519180092/0001193125-19-180092-index.htm
2019-07-23	S-3	Registration statement under Securities Act of 1933	https://www.sec.gov/Archives/edgar/data/1358403/000119312519200072/0001193125-19-200072-index.htm
2019-07-23	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1358403/000119312519200094/0001193125-19-200094-index.htm
2019-07-26	CORRESP	Correspondence	https://www.sec.gov/Archives/edgar/data/1358403/000119312519203047/0001193125-19-203047-index.htm
2019-08-15	FWP	Filing under Securities Act Rules 163/433 of free writing prospectuses	https://www.sec.gov/Archives/edgar/data/1358403/000119312519222608/0001193125-19-222608-index.htm
2019-08-16	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1358403/000119312519222902/0001193125-19-222902-index.htm
2019-08-16	FWP	Filing under Securities Act Rules 163/433 of free writing prospectuses	https://www.sec.gov/Archives/edgar/data/1358403/000119312519222904/0001193125-19-222904-index.htm
2019-08-19	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1358403/000119312519224574/0001193125-19-224574-index.htm
2019-08-19	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000119312519224579/0001193125-19-224579-index.htm
2019-08-26	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1358403/000119312519229442/0001193125-19-229442-index.htm
2019-11-25	PRE 14A	Other preliminary proxy statements	https://www.sec.gov/Archives/edgar/data/1358403/000119312519299951/0001193125-19-299951-index.htm
2019-12-05	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1358403/000119312519307293/0001193125-19-307293-index.htm
2019-12-05	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1358403/000119312519307300/0001193125-19-307300-index.htm
2019-12-19	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000119312519318128/0001193125-19-318128-index.htm
2019-12-31	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000119312519326672/0001193125-19-326672-index.htm
2020-01-14	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000119312520007200/0001193125-20-007200-index.htm
2020-02-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000119312520026926/0001193125-20-026926-index.htm
2020-10-29	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000119312520281180/0001193125-20-281180-index.htm
2020-10-30	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1358403/000119312520282788/0001193125-20-282788-index.htm
2020-11-02	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000119312520283250/0001193125-20-283250-index.htm
2018-12-20	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000120919118063786/0001209191-18-063786-index.htm
2018-12-20	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000120919118063787/0001209191-18-063787-index.htm
2018-12-20	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000120919118063788/0001209191-18-063788-index.htm
2018-12-20	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000120919118063791/0001209191-18-063791-index.htm
2019-09-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000120919119049227/0001209191-19-049227-index.htm
2020-01-14	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000120919120003350/0001209191-20-003350-index.htm
2019-01-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000006/0001358403-19-000006-index.htm
2019-01-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000007/0001358403-19-000007-index.htm
2019-01-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000008/0001358403-19-000008-index.htm
2019-01-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000009/0001358403-19-000009-index.htm
2019-01-04	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000010/0001358403-19-000010-index.htm
2019-02-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000018/0001358403-19-000018-index.htm
2019-02-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000019/0001358403-19-000019-index.htm
2019-02-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000020/0001358403-19-000020-index.htm
2019-02-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000021/0001358403-19-000021-index.htm
2019-02-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000022/0001358403-19-000022-index.htm
2019-02-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000023/0001358403-19-000023-index.htm
2019-02-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000024/0001358403-19-000024-index.htm
2019-02-07	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000026/0001358403-19-000026-index.htm
2019-02-20	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000028/0001358403-19-000028-index.htm
2019-03-12	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000035/0001358403-19-000035-index.htm
2019-03-12	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000038/0001358403-19-000038-index.htm
2019-03-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000041/0001358403-19-000041-index.htm
2019-04-10	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000044/0001358403-19-000044-index.htm
2019-04-25	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000047/0001358403-19-000047-index.htm
2019-04-26	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000050/0001358403-19-000050-index.htm
2019-04-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000051/0001358403-19-000051-index.htm
2019-05-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000056/0001358403-19-000056-index.htm
2019-05-07	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000058/0001358403-19-000058-index.htm
2019-05-15	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000060/0001358403-19-000060-index.htm
2019-05-30	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000062/0001358403-19-000062-index.htm
2019-06-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000066/0001358403-19-000066-index.htm
2019-06-04	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000069/0001358403-19-000069-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000077/0001358403-19-000077-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000078/0001358403-19-000078-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000079/0001358403-19-000079-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000080/0001358403-19-000080-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000081/0001358403-19-000081-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000082/0001358403-19-000082-index.htm
2019-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000083/0001358403-19-000083-index.htm
2019-06-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000091/0001358403-19-000091-index.htm
2019-06-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000092/0001358403-19-000092-index.htm
2019-06-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000093/0001358403-19-000093-index.htm
2019-06-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000094/0001358403-19-000094-index.htm
2019-06-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000095/0001358403-19-000095-index.htm
2019-06-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000096/0001358403-19-000096-index.htm
2019-06-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000097/0001358403-19-000097-index.htm
2019-07-29	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000099/0001358403-19-000099-index.htm
2019-08-05	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000104/0001358403-19-000104-index.htm
2019-08-05	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000106/0001358403-19-000106-index.htm
2019-08-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000111/0001358403-19-000111-index.htm
2019-08-23	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000112/0001358403-19-000112-index.htm
2019-08-30	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000114/0001358403-19-000114-index.htm
2019-11-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000121/0001358403-19-000121-index.htm
2019-11-06	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000123/0001358403-19-000123-index.htm
2020-01-29	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000004/0001358403-20-000004-index.htm
2020-02-05	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000005/0001358403-20-000005-index.htm
2020-03-12	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000006/0001358403-20-000006-index.htm
2020-03-12	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000007/0001358403-20-000007-index.htm
2020-04-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000008/0001358403-20-000008-index.htm
2020-04-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000009/0001358403-20-000009-index.htm
2020-04-17	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000010/0001358403-20-000010-index.htm
2020-04-17	PRE 14A	Other preliminary proxy statements	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000011/0001358403-20-000011-index.htm
2020-04-27	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000012/0001358403-20-000012-index.htm
2020-04-27	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000013/0001358403-20-000013-index.htm
2020-05-01	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000014/0001358403-20-000014-index.htm
2020-05-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000015/0001358403-20-000015-index.htm
2020-05-07	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000016/0001358403-20-000016-index.htm
2020-06-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000017/0001358403-20-000017-index.htm
2020-06-17	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000018/0001358403-20-000018-index.htm
2020-06-24	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000019/0001358403-20-000019-index.htm
2020-08-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000020/0001358403-20-000020-index.htm
2020-08-06	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000021/0001358403-20-000021-index.htm
2020-08-06	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000022/0001358403-20-000022-index.htm
2020-09-16	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000024/0001358403-20-000024-index.htm
2020-09-16	8-K/A	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000025/0001358403-20-000025-index.htm
2020-11-05	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000026/0001358403-20-000026-index.htm
2020-11-05	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1358403/000135840320000027/0001358403-20-000027-index.htm
2019-01-18	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1358403/000156761919001333/0001567619-19-001333-index.htm
2020-01-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020000160/0001628280-20-000160-index.htm
2020-01-15	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000162828020000355/0001628280-20-000355-index.htm
2020-01-21	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1358403/000162828020000398/0001628280-20-000398-index.htm
2020-02-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020000987/0001628280-20-000987-index.htm
2020-02-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020000991/0001628280-20-000991-index.htm
2020-02-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020000993/0001628280-20-000993-index.htm
2020-03-19	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020003793/0001628280-20-003793-index.htm
2020-04-09	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020004834/0001628280-20-004834-index.htm
2020-04-09	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020004836/0001628280-20-004836-index.htm
2020-04-09	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020004837/0001628280-20-004837-index.htm
2020-04-09	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020004838/0001628280-20-004838-index.htm
2020-04-09	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020004839/0001628280-20-004839-index.htm
2020-06-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020008801/0001628280-20-008801-index.htm
2020-06-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020009546/0001628280-20-009546-index.htm
2020-06-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020009547/0001628280-20-009547-index.htm
2020-06-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020009548/0001628280-20-009548-index.htm
2020-06-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020009549/0001628280-20-009549-index.htm
2020-06-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020009550/0001628280-20-009550-index.htm
2020-06-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000162828020009551/0001628280-20-009551-index.htm
2020-01-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000170524620000002/0001705246-20-000002-index.htm
2020-02-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000170524620000004/0001705246-20-000004-index.htm
2020-01-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000176787720000002/0001767877-20-000002-index.htm
2020-02-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000176787720000004/0001767877-20-000004-index.htm
2019-11-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000177394419000002/0001773944-19-000002-index.htm
2020-02-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1358403/000179986920000002/0001799869-20-000002-index.htm
2019-07-30	EFFECT	Notice of Effectiveness	https://www.sec.gov/Archives/edgar/data/1358403/999999999519001735/9999999995-19-001735-index.htm
2019-02-19	CT ORDER	Confidential treatment order	https://www.sec.gov/Archives/edgar/data/1358403/999999999719000428/9999999997-19-000428-index.htm
2019-04-12	CT ORDER	Confidential treatment order	https://www.sec.gov/Archives/edgar/data/1358403/999999999719002854/9999999997-19-002854-index.htm
2019-08-02	CT ORDER	Confidential treatment order	https://www.sec.gov/Archives/edgar/data/1358403/999999999719006364/9999999997-19-006364-index.htm
2020-03-03	CT ORDER	Confidential treatment order	https://www.sec.gov/Archives/edgar/data/1358403/999999999720001116/9999999997-20-001116-index.htm
2020-03-03	CT ORDER	Confidential treatment order	https://www.sec.gov/Archives/edgar/data/1358403/999999999720001117/9999999997-20-001117-index.htm

Bellicum Pharmaceuticals, Inc (BLCM) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bellicum Pharmaceuticals, Inc (BLCM). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 32%
Institutional Ownership: 2390%

Transaction Date	Insider Name	Insider Title	Type	Shares Number	Shares Price	Total Transaction	Shares Held After Transaction	Link
2019-01-02	Gregory S. Naeve	Chief Business Officer	Buy	2,031.00			15,434.00	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000009/0001358403-19-000009-index.htm
2019-08-29	Shane Ward	Sr. VP and General Counsel	Buy	8,000.00	1.23	9,821.60	18,294.00	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000114/0001358403-19-000114-index.htm
2019-08-21	Richard A. Fair	President and CEO	Buy	20,000.00	0.99	19,780.00	26,561.00	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000111/0001358403-19-000111-index.htm
2019-01-02	Alan K. Smith	EVP, Technical Operations	Buy	2,344.00			4,431.00	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000006/0001358403-19-000006-index.htm
2019-01-02	Rosemary Y. Williams	Principal Accounting Officer	Buy	1,281.00			4,467.00	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000008/0001358403-19-000008-index.htm
2019-01-03	Rosemary Y. Williams	Principal Accounting Officer	Buy	782.00			4,766.00	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000008/0001358403-19-000008-index.htm
2020-03-17	Richard A. Fair	President and CEO	Buy	5,000.00	4.00	19,998.50	5,000.00	https://www.sec.gov/Archives/edgar/data/1358403/000162828020003793/0001628280-20-003793-index.htm
2019-01-03	Alan K. Smith	EVP, Technical Operations	Buy	1,562.00			5,110.00	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000006/0001358403-19-000006-index.htm
2020-01-02	Rosemary Y. Williams	VP, Finance & PAO	Buy	1,282.00			5,753.00	https://www.sec.gov/Archives/edgar/data/1358403/000162828020000160/0001628280-20-000160-index.htm
2020-01-03	Rosemary Y. Williams	VP, Finance & PAO	Buy	781.00			6,051.00	https://www.sec.gov/Archives/edgar/data/1358403/000162828020000160/0001628280-20-000160-index.htm
2019-09-10	Richard A. Fair	President and CEO	Buy	40,000.00	1.25	50,000.00	66,561.00	https://www.sec.gov/Archives/edgar/data/1358403/000120919119049227/0001209191-19-049227-index.htm
2020-01-02	Alan K. Smith	EVP, Technical Operations	Buy	2,344.00			6,865.00	https://www.sec.gov/Archives/edgar/data/1358403/000170524620000002/0001705246-20-000002-index.htm
2019-11-13	Jr Joseph Paul Woodard	SVP Clinical & Medical Affairs	Buy	3,750.00			7,064.00	https://www.sec.gov/Archives/edgar/data/1358403/000177394419000002/0001773944-19-000002-index.htm
2020-01-03	Aaron E. Foster	Sr VP, Head of Research	Buy	625.00			7,517.00	https://www.sec.gov/Archives/edgar/data/1358403/000176787720000002/0001767877-20-000002-index.htm
2020-01-03	Alan K. Smith	EVP, Technical Operations	Buy	1,563.00			7,545.00	https://www.sec.gov/Archives/edgar/data/1358403/000170524620000002/0001705246-20-000002-index.htm
2020-01-02	Aaron E. Foster	Sr VP, Head of Research	Buy	2,500.00			7,834.00	https://www.sec.gov/Archives/edgar/data/1358403/000176787720000002/0001767877-20-000002-index.htm
2019-01-02	David M. Spencer	Chief Technology Officer	Buy	2,500.00			92,439.00	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000007/0001358403-19-000007-index.htm
2019-01-03	David M. Spencer	Chief Technology Officer	Buy	1,562.00			93,059.00	https://www.sec.gov/Archives/edgar/data/1358403/000135840319000007/0001358403-19-000007-index.htm

Bellicum Pharmaceuticals, Inc

(NASDAQ:BLCM)